Table 1 Demographical data of 52 patients with eribulin chemotherapy for locally advanced or metastatic breast cancer
Parameters (n = 52) | Number of patients (%) |
|---|---|
Age (years old) | 63.5 ± 12.7 |
Degree of progress | |
Locally advanced / Visceral metastases | 13 (25.0%) / 39 (75.0%) |
Site of metastases | |
Lung / Bone / Liver | 19 (36.5%) / 19 (36.5%) / 18 (34.6. %) |
Life threatening condition | |
Life threatening / non- Life threatening | 14 (26.9%) / 38 (73.1%) |
Nuclear grade | |
1 / 2 / 3 | 13 (25.0%) / 20 (38.5%) / 19 (36.5%) |
Estrogen receptor | |
Negative / Positive | 25 (48.1%) / 27 (51.9%) |
Progesterone receptor | |
Negative / Positive | 32 (61.5%) / 20 (38.5%) |
HER2 | |
Negative / Positive | 47 (90.4%) / 5 (9.6%) |
Ki67 | |
Negative / Positive | 26 (50.0%) / 26 (50.0%) |
Intrinsic subtype | |
Luminal A/Luminal B/Luminal HER2/HER2 enriched/TNBC | 12 (23.1%) / 13 (15.0%) / 2 (3.8%) / 3 (5.8%) / 22 (42.3%) |